Ardelyx opts out of CMS TDAPA for XPHOZAH, foregoing add-on payment

ARDELYX, INC.

Ardelyx will not apply to include XPHOZAH (tenapanor) in CMS ESRD PPS TDAPA program.
Decision aimed at preserving patient access to the phosphate absorption inhibitor.
By opting out, XPHOZAH will not receive transitional add-on payment from Medicare.
Announcement made on July 2, 2024; no financial guidance provided on impact.
Company expects to rely on standard ESRD PPS bundled payment for XPHOZAH.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.